Co-delivery of Paclitaxel and TOS-cisplatin Via TAT-targeted Solid Lipid Nanoparticles with Synergistic Antitumor Activity Against Cervical Cancer

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2017 Feb 17

PMID 28203075

Citations 40

Authors

Bo Liu

Li Han

Junyan Liu

Shumei Han

Zhen Chen

Lixi Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Cervical cancer is a major world health problem for women. Currently, cancer research focuses on improving therapy for cervical cancer using various treatment options such as co-delivery of chemotherapeutic agents by nanocarriers.

Purpose: The aim of this study was to develop trans-activating transcriptional activator (TAT)-modified solid lipid nanoparticles (SLNs) for co-delivery of paclitaxel (PTX) and α-tocopherol succinate-cisplatin prodrug (TOS-CDDP) (TAT PTX/TOS-CDDP SLNs) in order to achieve synergistic antitumor activity against cervical cancer.

Methods: Lipid prodrug of CDDP (TOS-CDDP) and TAT-containing polyethylene glycol-distearoyl-phosphatidylethanolamine (TAT-PEG-DSPE) were synthesized. TAT PTX/TOS-CDDP SLNs were prepared by emulsification and solvent evaporation method. Physicochemical characteristics of SLNs such as size, morphology, and release profiles were explored. In vitro and in vivo studies were carried out to assess the efficacy of their antitumor activity in target cells.

Results: TAT PTX/TOS-CDDP SLNs could be successfully internalized by HeLa cells and showed a synergistic effect in the suppression of cervical tumor cell growth. They exhibited high tumor tissue accumulation, superior antitumor efficiency, and much lower toxicity in vivo.

Conclusion: The present study indicates that the co-delivery system provides a promising platform as a combination therapy for the treatment of cervical cancer, and possibly other types of cancer as well.

Citing Articles

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

(Nano)biotechnological approaches in the treatment of cervical cancer: integration of engineering and biology.

Xie W, Xu Z Front Immunol. 2024; 15:1461894.

PMID: 39346915 PMC: 11427397. DOI: 10.3389/fimmu.2024.1461894.

Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations.

Nathani A, Sun L, Khan I, Aare M, Bagde A, Li Y Pharmaceutics. 2024; 16(1).

PMID: 38258094 PMC: 10821370. DOI: 10.3390/pharmaceutics16010083.

Application of Nanoparticles in Cancer Treatment: A Concise Review.

Sell M, Lopes A, Escudeiro M, Esteves B, Monteiro A, Trindade T Nanomaterials (Basel). 2023; 13(21).

PMID: 37947732 PMC: 10650201. DOI: 10.3390/nano13212887.

A Straightforward Method for the Development of Positively Charged Gold Nanoparticle-Based Vectors for Effective siRNA Delivery.

Elizarova T, Antopolsky M, Novichikhin D, Skirda A, Orlov A, Bragina V Molecules. 2023; 28(8).

PMID: 37110552 PMC: 10144622. DOI: 10.3390/molecules28083318.

References

Zhang W, Li C, Shen C, Liu Y, Zhao X, Liu Y . Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment. Drug Deliv. 2015; 23(7):2575-2580. DOI: 10.3109/10717544.2015.1035466. View

Lv S, Tang Z, Li M, Lin J, Song W, Liu H . Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials. 2014; 35(23):6118-29. DOI: 10.1016/j.biomaterials.2014.04.034. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Hani U, Osmani R, Bhosale R, Shivakumar H, Kulkarni P . Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review. Curr Drug Targets. 2015; 17(3):337-52. DOI: 10.2174/1389450116666150505154720. View

Arias J, Reddy L, Othman M, Gillet B, Desmaele D, Zouhiri F . Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano. 2011; 5(2):1513-21. DOI: 10.1021/nn1034197. View

Ruoslahti E . Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev. 2016; 110-111:3-12. PMC: 5045823. DOI: 10.1016/j.addr.2016.03.008. View

Ye J, Wang A, Liu C, Chen Z, Zhang N . Anionic solid lipid nanoparticles supported on protamine/DNA complexes. Nanotechnology. 2011; 19(28):285708. DOI: 10.1088/0957-4484/19/28/285708. View

Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X . Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2015; 23(8):2720-2725. DOI: 10.3109/10717544.2015.1058434. View

Mi Y, Zhao J, Feng S . Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int J Pharm. 2012; 438(1-2):98-106. DOI: 10.1016/j.ijpharm.2012.08.038. View

10.

Choi J, Ko E, Chung H, Lee J, Ju E, Lim H . Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs. Int J Nanomedicine. 2015; 10:6121-32. PMC: 4598197. DOI: 10.2147/IJN.S88375. View

11.

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

12.

Duhem N, Danhier F, Pourcelle V, Schumers J, Bertrand O, Leduff C . Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity. Bioconjug Chem. 2013; 25(1):72-81. DOI: 10.1021/bc400326y. View

13.

Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T . Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014; 194:228-37. DOI: 10.1016/j.jconrel.2014.09.005. View

14.

Prabaharan M, Grailer J, Pilla S, Steeber D, Gong S . Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials. 2009; 30(29):5757-66. DOI: 10.1016/j.biomaterials.2009.07.020. View

15.

Mabuchi S, Isohashi F, Yokoi T, Takemura M, Yoshino K, Shiki Y . A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol. 2016; 141(2):240-246. DOI: 10.1016/j.ygyno.2016.02.011. View

16.

Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S . A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014; 133(1):117-23. DOI: 10.1016/j.ygyno.2014.01.042. View

17.

Weber S, Zimmer A, Pardeike J . Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2013; 86(1):7-22. DOI: 10.1016/j.ejpb.2013.08.013. View

18.

Gao M, Xu Y, Qiu L . Enhanced combination therapy effect on paclitaxel-resistant carcinoma by chloroquine co-delivery via liposomes. Int J Nanomedicine. 2015; 10:6615-32. PMC: 4622487. DOI: 10.2147/IJN.S91463. View

19.

Zeng X, Tao W, Mei L, Huang L, Tan C, Feng S . Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials. 2013; 34(25):6058-67. DOI: 10.1016/j.biomaterials.2013.04.052. View

20.

Kelland L, Barnard C, Evans I, Murrer B, Theobald B, Wyer S . Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem. 1995; 38(16):3016-24. DOI: 10.1021/jm00016a004. View